Lupin will be launching the generic version of Yasmin, a brand of Bayer Healthcare.
Lupin's drospirenone and ethinyl estradiol tablet is a combined oral contraceptive, used to prevent pregnancy.
In the US, Yasmin generates annual sales of $275 million.
This is a big approval, as the product has the potential to generate sales of $50 million and $10 million in profits annually, said T Ranvir Singh of Sharekhan.
Conservative estimates suggest the company will be able to garner 10 per cent of the market share in the coming year, which adds up to $27.5 million.
The product is likely to be launched immediately and the revenues will flow in from the
Indian pleads guilty in $13.8 mn US healthcare fraud
Indian woman gets 20-yr jail term for US healthcare fraud
View: Absurd to deny Narendra Modi a US visa
Register for College Hunt USA and live the American dream
This is how Lupin cracked the Japanese pharma market